Update as of 06 November 2024 : Since the public consultation and appeals period for the HTA Council Preliminary Recommendation on Dapivirine Vaginal Ring, Donepezil Hydrochloride, Tenofovir/Lamivudine/Dolutegravir and Tenofovir + Lamivudine in combination with Dolutegravir ended on 05 November 2024 without appeals received, this preliminary HTA Council recommendation lapsed into the Final Recommendation and was transmitted to the Secretary of continue reading : HTA Council Preliminary Recommendation on Dapivirine Vaginal Ring, Donepezil Hydrochloride, Tenofovir/Lamivudine/Dolutegravir and Tenofovir + Lamivudine in combination with Dolutegravir
CALL FOR PROPOSALS: HTA Research Agenda Program [HTA Research Topics 2024 – UPDATED Batch 3 (FEC topics and Cycle 1 topics for Economic Assessments and Ethical, Legal, Social, and Health Systems Implication (ELSHI) Assessments] [CLOSED]
Note: This call for proposals closed on 22 November 2024. This call consists of prioritized health technology topics that underwent clinical assessment under the HTA general track and are proceeding to the following assessments: The Health Technology Assessment (HTA) Philippines invites interested researchers to submit capsule proposals under the HTA Research Agenda Program: 2024 HTA Topics continue reading : CALL FOR PROPOSALS: HTA Research Agenda Program [HTA Research Topics 2024 – UPDATED Batch 3 (FEC topics and Cycle 1 topics for Economic Assessments and Ethical, Legal, Social, and Health Systems Implication (ELSHI) Assessments] [CLOSED]
CALL FOR PROPOSALS FOR HTA of 2022 PRIORITY MENTAL HEALTH DRUGS IN COLLABORATION WITH WHO [CLOSED]
Note: This call for proposals closed on 14 October 2024. The HTA Philippines, in collaboration with the WHO, is now calling for proposals for the health technology assessment of 2022 priority mental health drugs for inclusion in the Philippine National Formulary. Call for submissions will run from October 2 – 14, 2024 For more details, and continue reading : CALL FOR PROPOSALS FOR HTA of 2022 PRIORITY MENTAL HEALTH DRUGS IN COLLABORATION WITH WHO [CLOSED]
[FOR PUBLIC CONSULTATION] HTA Council Preliminary Recommendation on Reteplase (10 units lyophilized powder for IV injection) for ST-Elevation Myocardial Infarction (STEMI) Patients
Published on 01 October 2024 As of 23 September 2024, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of Reteplase (10 units lyophilized powder for IV injection) for ST-Elevation Myocardial Infarction (STEMI) Patients for possible inclusion in the Philippine National Formulary (PNF). As such, the HTA Council hereby makes continue reading : [FOR PUBLIC CONSULTATION] HTA Council Preliminary Recommendation on Reteplase (10 units lyophilized powder for IV injection) for ST-Elevation Myocardial Infarction (STEMI) Patients
STATUS UPDATES ON THE HTA NOMINATIONS FOR CYCLE 3 TOPICS
We would like to inform our stakeholders that the HTA Council will accept nominations only from the Department of Health (DOH) and Philippine Health Insurance Corporation (PhilHealth) in 2024, and open the Call for Nominations to other stakeholders in the 4th quarter of 2025 for Cycle 3 Topics based on the status of ongoing assessments. continue reading : STATUS UPDATES ON THE HTA NOMINATIONS FOR CYCLE 3 TOPICS